Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.129 +0.019 (+0.46%)
Streaming Delayed Price Updated: 9:52 AM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery... 
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
News headline image
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. ↗
Most of Nvidia's AI bets are riding on one stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
What Analysts Are Saying About Recursion Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Recursion Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts ↗
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
News headline image
3 AI Stocks Disrupting Trillion-Dollar Industries ↗
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today ↗
This AI company isn't yet living up to the hype. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell ↗
There might be better artificial intelligence (AI) stocks out there to buy. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode ↗
The artificial intelligence revolution is leaving no opportunity unaddressed. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Recursion Pharmaceuticals Stock Caught a Cold This Week ↗
The few news items from and about the company weren't all that positive. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
These companies are in the right place at the right time with the right products. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Recursion Pharmaceuticals Stock Tanked on Tuesday ↗
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest. 
Via The Motley Fool
News headline image
Recursion (RXRX) Q2 Revenue Jumps 33% ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates ↗
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share,... 
Via Benzinga
News headline image
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss ↗
Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi... 
Via Chartmill
News headline image
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Beaten-Down Stocks With Incredible Upside Potential ↗
Getting in on the ground floor with these companies might lead to superior returns. 
Via The Motley Fool
News headline image
Why Recursion Pharmaceuticals Stock Got Mashed on Monday ↗
Investors weren't cheered by news from one of the biotech's rivals. 
Via The Motley Fool
News headline image
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
News headline image
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles. 
Via Benzinga
News headline image
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Biocomputers: The Future of Computing is Alive
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes... 
Via MarketMinute
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.